Real-Time Drug Trial Data Could Change How Medicines Get Approved

For decades, drug testing followed the same slow rhythm. Researchers ran trials in stages, then paused for months to analyze data before asking regulators for the next step. Patients waited years for treatments while paperwork piled up. Now, a new FDA approach cuts out the waiting by letting regulators see trial results instantly. This live-data system uses AI to spot risks or successes the moment they happen, not after months of delays. The goal? Faster drug approvals and fewer cases where patients miss out because a critical finding took too long to surface. Two major trials are already testing this method. One checks a new lymphoma drug from AstraZeneca, while another examines a lung cancer treatment from Amgen. Both projects feed real-time safety signals straight to the FDA, proving the system works outside of theory. The technology comes from companies like Paradigm Health, which built an AI tool that pulls data from hospital records and other sources automatically. Instead of manual reports, regulators get instant updates.Officials behind the change admit the old method was outdated. "Sixty years of waiting for reports slowed down decisions we didn’t need to wait for, " one leader noted. The shift isn’t just about speed, either. Catching side effects early could save lives by stopping harmful drugs from staying on the market too long. But the system also raises questions. Can AI catch every risk without human oversight? Will hospitals with older records slow down the process? The FDA isn’t rushing blindly ahead. It’s asking scientists and drugmakers for feedback on how to expand this pilot program safely. By summer, a larger trial of the system will begin, with rules shaped by those who actually use it. The faster we test and approve safe drugs, the faster people get the treatments they need—but only if the technology can prove itself beyond these early trials.